Highlights Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Market Closed - Nyse Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.3707 ^USD	-0.88%		+1.84%	-13.81%

May. 07	Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 23	Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Theriva Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma	Apr. 23	CI
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma	Feb. 07	CI
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Theriva?? Biologics and Sant Joan de Deu-Bar Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer	Nov. 02	CI
Theriva? Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023	23-10-23	CI
Theriva Biologics, Inc. Announces Presentation at Esmo Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating Vcn-01 in Combination with Durvalumab in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck	23-10-17	CI
Theriva Biologics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Theriva Biologics Announces Key Progress in Virage, an Ongoing, Multinational Phase 2B Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma	23-08-02	CI
Theriva Biologics Says US FDA Grants Orphan Drug Designation to VCN-01 for Pancreatic Cancer Treatment; Shares Surge	23-06-27	MT
Theriva Biologics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Theriva Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Theriva Biologics, Inc. Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 in Allogeneic Hematopoietic Cell Transplant Recipients	23-02-16	CI
Theriva Biologics, Inc. Announces First Patient Dosed in VIRAGE, A Phase 2B Trial of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma	23-01-17	CI
Theriva Biologics Announces Dosing of First Patient in the Investigator Sponsored Phase 1 Trial of VCN-01, an Intravenous Oncolytic Adenovirus, in Patients with Brain Tumors	23-01-09	CI
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Theriva Biologics Announces First Patient Dosed in Second Cohort of Phase 1b/2a Clinical Trial of SYN-004	22-11-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Theriva Biologics, Inc.

Equities

TOVX

US87164U4094

Highlights

Filters